Drug intelligence / Profile preview

amoxicillin + levofloxacin + furazolidone

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

A combination antibiotic therapy used primarily for the eradication of Helicobacter pylori infection. This regimen is typically administered with a proton pump inhibitor (such as rabeprazole) as a quadruple therapy. Studies have shown this combination to be highly effective with eradication rates of up to 94.3% (per-protocol analysis), significantly higher than standard triple therapy. The combination is generally well-tolerated with mild side effects such as dizziness, nausea, and diarrhea.

Targets

DNA gyraseAzR (Bacterial azoreductase)PBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on amoxicillin + levofloxacin + furazolidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + levofloxacin + furazolidone.

Explore the full profile